Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;5(Suppl 2):82-92.
doi: 10.2174/1874104501105010082. Epub 2011 Sep 9.

Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus

Mohamed Lotfy  1 , Jaipaul Singh, Huba Kalász, Kornelia Tekes, Ernest Adeghate
Affiliations

Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus

Mohamed Lotfy et al. Open Med Chem J. 2011.

Abstract

Diabetes mellitus (DM) is a major metabolic disorder currently affecting over 200 million people worldwide. Approximately 90% of all diabetic patients suffer from Type 2 diabetes mellitus (T2DM). The world's economy coughs out billions of dollars annually to diagnose, treat and manage patients with diabetes. It has been shown that the naturally occurring gut hormones incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) can preserve the morphology and function of pancreatic beta cell. In addition, GIP and GLP-1 act on insulin receptors to facilitate insulin-receptor binding, resulting in optimal glucose metabolism. This review examines the medicinal chemistry and roles of incretins, specifically, GLP-1 and drugs which can mimic its actions and prevent its enzymatic degradation. The review discussed GLP-1 agonists such as exenatide, liraglutide, taspoglutide and albiglutide. The paper also identified and reviewed a number of inhibitors, which can block dipeptidyl peptidase 4 (DPP-4), the enzyme responsible for the rapid degradation of GLP-1. These DPP-4 inhibitors include sitagliptin, saxagliptin, vildagliptin and many others which are still in the experimental phase.

Keywords: DPP-4 inhibitors; Incretins; medicinal chemistry.; type 2 diabetes.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Amino acid sequence of GLP-1 (a) and exenatide (b).
Fig. (2)
Fig. (2)
Chemical structure of Liraglutide and Albiglutide.
See this image and copyright information in PMC

References

    1. D’Souza A, Hussain M, Howarth FC, Woods NM, Bidasee K, Singh J. Pathogenesis and pathophysiology of accelerated atherosclerosis in the diabetic heart. Mol. Cell Biochem. 2009;331:89–116. - PubMed
    1. Kumar PJ, Clark M. Diabetes mellitus and other disorders of metabolism. In: Kumar PJ, Clark M, editors. Textbook of Medicine. Saunders: London; pp. 1069–1122.
    1. Havale SH, Pal M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg. Med. Chem. 2009;17:1783–1802. - PubMed
    1. Amos A, McCarty D, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet. Med. 1997;14:S1–S85. - PubMed
    1. Zimmet PZ, Alberti KG. Globalisation and the noncommunicable disease epidemic. Obesity. 2006;14:1–3. - PubMed

LinkOut - more resources